Use of aromatase inhibitors in short children and adolescents to increase height gain: A current practice survey and review of the literature
Authors' conclusion
This survey indicates that the use of AI among endocrinologists in patients with short stature or short PAH is increasing as more studies have come to light. However, questions remain regarding long-term outcomes, highlighting the need for future trials to further reassure its safety and effectiveness.
Study context
- Population
- Endocrinologists from 23 countries (mostly South America) managing pediatric patients with short stature or short predicted adult height (PAH)
- Participants
- 243 participants23 countries
- Outcome
- Real-world use of AI in pediatric patients with short stature or short PAH
Methodological detailsdescriptive, questionnaire-based, convenience sampling
- Descriptive
- Questionnaire-based
- Convenience sampling
Main finding
As reported in the abstract
Real-world use of AI
Indicated AI to improve PAH
71.6%
Used AI in prepubertal patients (most common indication: boys with CAH)
25.9%
Used AI in pubertal patients with short stature and short PAH, regardless of cause, mostly combined with GH
92%
Observational data: associations, not effects.
Safety
Discontinuation due to adverse effects
- Clinicians who had to discontinue treatment due to adverse effects
- One-fifth
Original publication
Use of aromatase inhibitors in short children and adolescents to increase height gain: A current practice survey and review of the literature. Horm Res Paediatr. Published 30 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →